UK Becomes First Country to Secure Zero-Tariff Pharma Deal with US as NHS Faces Higher Medicine Costs
The United Kingdom has finalised a landmark pharmaceutical trade deal with the United States that grants tariff-free access for UK-made medicines to the US market for at least three years — making Britain the first country in the world to secure a 0% tariff on pharmaceutical exports to the US — but critics warn the agreement will cost the NHS billions of pounds in higher medicine prices.
The deal, whose full text was agreed on 2 April 2026, protects approximately £5 billion in annual UK pharmaceutical exports from US tariffs and is expected to safeguard 50,000 pharmaceutical jobs in Britain. However, in exchange, the NHS will pay 25% more for new medicines launched after April 2026, and the UK has committed to significantly increasing its medicines spending as a proportion of GDP.
Background
The pharmaceutical provisions of the deal were negotiated separately from a wider US-British trade agreement signed in June 2025, with outline terms announced in December. The agreement comes as the Trump administration has threatened to impose sweeping tariffs on pharmaceutical imports, which would have significantly impacted UK drug exports to the US — one of the most important markets for British pharmaceutical companies including AstraZeneca and GSK.
Key Developments
Under the terms of the deal, UK pharmaceutical exports to the US — including drug ingredients and certain medical technologies — will be exempt from tariffs, including potential US Section 232 sectoral tariffs and any future Section 301 country-specific tariffs, through January 2029. The tariff exemption is conditional on major UK pharmaceutical companies complying with separate US government pricing and tariff agreements.
In exchange, the NHS will increase the net price paid for new medicines by 25% from April 2026. The cost-effectiveness threshold used by the National Institute for Health and Care Excellence (NICE) has been increased from a range of £20,000-£30,000 per quality-adjusted life year (QALY) to £25,000-£35,000 per QALY. The UK has also pledged to increase its medicines spending from 0.3% of GDP to 0.35% by 2028 and further to 0.6% by 2035.
The government described the deal as a "win for British patients, British businesses and the British economy," pointing to two new cancer medicines already recommended under the updated NICE approach. Industry responses have been cautiously optimistic, with companies including Bristol Myers Squibb, AbbVie, and GSK welcoming the finalisation of the partnership.
Why It Matters
Critics, including Dr Andrew Hill from the University of Liverpool, have raised concerns about the cost to the NHS, estimating that the increased spending on medicines could cost the UK £9 billion annually by 2035. The Liberal Democrats have called for parliamentary scrutiny of the deal, fearing increased US influence over NHS medicine pricing.
The agreement also includes provisions for closer cooperation between the UK's Medicines and Healthcare products Regulatory Agency (MHRA) and the US Food and Drug Administration (FDA), including efforts to align medical device regulation to speed up patient access to new technologies.
What's Next
The deal will be subject to parliamentary scrutiny in the coming weeks. The government has indicated that the agreement will accelerate NHS patients' access to new medicines, with further announcements expected on specific treatments that will benefit from the updated NICE framework. Full details from The Guardian.
